

## Pharmacy Formulary Updates for May 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in May 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Xerava	MB
Revcovi	MB
Ultomiris	MB;PA
Gamifant	MB
levorphanol tartrate 3 mg	NC;QL
Khapzory	MB
Udenyca	T2;PA;QL;SP
buprenorphine-naloxone films	T2;PA
Suboxone	NC
minocycline SR 80, 105 mg	T3
cyclobenzaprine ER capsules	NC
aliskiren fumarate	T2
Tekturna	NC
diclofenac epolamine 1.3% patches	NC
Ganirelix (brand)	NC;SP
Thyrogen	MB

**Key:**

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy